Literature DB >> 19057201

WHIM syndrome: congenital immune deficiency disease.

Toshinao Kawai1, Harry L Malech.   

Abstract

PURPOSE OF REVIEW: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is characterized by susceptibility to human papilloma virus infection-induced warts and carcinomas; neutropenia, B-cell lymphopenia and hypogammaglobulinema-related infections; and bone marrow myelokathexis (myeloid hyperplasia with apoptosis). The purpose of this report is to review new findings about WHIM. RECENT
FINDINGS: Most WHIM patients have heterozygous C-terminus deletion mutations of the intracellular carboxy terminus of the chemokine receptor CXCR4. WHIM leukocytes have enhanced responses to CXCL12, the cognate ligand of CXCR4. Enhanced activity of CXCR4 delays release of mature neutrophils from bone marrow, resulting in neutropenia and apoptosis of mature neutrophils retained in the marrow. Finding two patients with WHIM who do not have detectable mutations of CXCR4 but whose cells are hyperresponsive to CXCL12 raises the possibility that there is more than one genetic basis for WHIM. One patient had low levels of G-protein receptor kinase 3, and the functional hyperactivity response to CXCL12 was corrected by forced gene transfer-mediated overexpression of G-protein receptor kinase 3, implicating defects in function of this protein as a potential alternate genetic cause of WHIM.
SUMMARY: Subjects reviewed include clinical presentation, diagnosis, and treatment of WHIM and advances in understanding the genetic basis of WHIM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19057201      PMCID: PMC2673024          DOI: 10.1097/MOH.0b013e32831ac557

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  58 in total

Review 1.  International union of pharmacology. XXII. Nomenclature for chemokine receptors.

Authors:  P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

2.  WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.

Authors:  Toshinao Kawai; Uimook Choi; Lanise Cardwell; Suk See DeRavin; Nora Naumann; Narda L Whiting-Theobald; Gilda F Linton; Jaehyun Moon; Philip M Murphy; Harry L Malech
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

Review 3.  Transduction of receptor signals by beta-arrestins.

Authors:  Robert J Lefkowitz; Sudha K Shenoy
Journal:  Science       Date:  2005-04-22       Impact factor: 47.728

4.  The role of a mutation of the CXCR4 gene in WHIM syndrome.

Authors:  Shoichiro Taniuchi; Midori Masuda; Yoshimitsu Fujii; Katsuhiko Izawa; Hirokazu Kanegane; Yohnosuke Kobayashi
Journal:  Haematologica       Date:  2005-09       Impact factor: 9.941

5.  Separate elements are required for ligand-dependent and -independent internalization of metastatic potentiator CXCR4.

Authors:  Yuko Futahashi; Jun Komano; Emiko Urano; Toru Aoki; Makiko Hamatake; Kosuke Miyauchi; Takeshi Yoshida; Yoshio Koyanagi; Zene Matsuda; Naoki Yamamoto
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

Review 6.  Regulation of receptor trafficking by GRKs and arrestins.

Authors:  Catherine A C Moore; Shawn K Milano; Jeffrey L Benovic
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

7.  Sporadic case of warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome.

Authors:  Michael D Tarzi; Michael Jenner; Keith Hattotuwa; Asma Z Faruqi; George A Diaz; Hilary J Longhurst
Journal:  J Allergy Clin Immunol       Date:  2005-10-10       Impact factor: 10.793

8.  Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors.

Authors:  A A Aprikyan; W C Liles; J R Park; M Jonas; E Y Chi; D C Dale
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

9.  Recurrent CXCR4 sequence variation in a girl with WHIM syndrome.

Authors:  Krisztina Alapi; Melinda Erdos; Gabriella Kovács; László Maródi
Journal:  Eur J Haematol       Date:  2006-11-06       Impact factor: 2.997

10.  Epstein-Barr virus-associated T-lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Warts, hypogammaglobulinemia, infections, and myelokathexis.

Authors:  S Imashuku; A Miyagawa; T Chiyonobu; H Ishida; T Yoshihara; T Teramura; K Kuriyama; T Imamura; S Hibi; A Morimoto; S Todo
Journal:  Ann Hematol       Date:  2002-07-20       Impact factor: 3.673

View more
  68 in total

Review 1.  Regulation of neutrophil trafficking from the bone marrow.

Authors:  Ryan B Day; Daniel C Link
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

2.  WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

Authors:  Qian Liu; Haoqian Chen; Teresa Ojode; Xiangxi Gao; Sandra Anaya-O'Brien; Nicholas A Turner; Jean Ulrick; Rosamma DeCastro; Corin Kelly; Adela R Cardones; Stuart H Gold; Eugene I Hwang; Daniel S Wechsler; Harry L Malech; Philip M Murphy; David H McDermott
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

3.  Chromothriptic cure of WHIM syndrome.

Authors:  David H McDermott; Ji-Liang Gao; Qian Liu; Marie Siwicki; Craig Martens; Paejonette Jacobs; Daniel Velez; Erin Yim; Christine R Bryke; Nancy Hsu; Zunyan Dai; Martha M Marquesen; Elina Stregevsky; Nana Kwatemaa; Narda Theobald; Debra A Long Priel; Stefania Pittaluga; Mark A Raffeld; Katherine R Calvo; Irina Maric; Ronan Desmond; Kevin L Holmes; Douglas B Kuhns; Karl Balabanian; Françoise Bachelerie; Stephen F Porcella; Harry L Malech; Philip M Murphy
Journal:  Cell       Date:  2015-02-05       Impact factor: 41.582

4.  Plerixafor for the Treatment of WHIM Syndrome.

Authors:  David H McDermott; Diana V Pastrana; Katherine R Calvo; Stefania Pittaluga; Daniel Velez; Elena Cho; Qian Liu; Hugh H Trout; João F Neves; Pamela J Gardner; David A Bianchi; Elizabeth A Blair; Emily M Landon; Susana L Silva; Christopher B Buck; Philip M Murphy
Journal:  N Engl J Med       Date:  2019-01-10       Impact factor: 91.245

5.  A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.

Authors:  Alessandra Handisurya; Christina Schellenbacher; Bärbel Reininger; Frieder Koszik; Philipp Vyhnanek; Andreas Heitger; Reinhard Kirnbauer; Elisabeth Förster-Waldl
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

Review 6.  Recent insights into the pathobiology of innate immune deficiencies.

Authors:  Sergio D Rosenzweig; Steven M Holland
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

Review 7.  Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind.

Authors:  Bertrand Boisson; Pierre Quartier; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2015-01-31       Impact factor: 7.486

Review 8.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

9.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

10.  Combined immunodeficiency associated with DOCK8 mutations.

Authors:  Qian Zhang; Jeremiah C Davis; Ian T Lamborn; Alexandra F Freeman; Huie Jing; Amanda J Favreau; Helen F Matthews; Joie Davis; Maria L Turner; Gulbu Uzel; Steven M Holland; Helen C Su
Journal:  N Engl J Med       Date:  2009-09-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.